Skip to content

Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement

Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02288663
Acronym
FREAGE
Enrollment
220
Registered
2014-11-11
Start date
2014-11-03
Completion date
2022-11-02
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Function

Brief summary

Glomerular filtration rate (GFR) is the recommended parameter to assess renal function. The reference technique to measure GFR (clearance of a glomerular agent) is not commonly used. Instead, estimations (eGFR) are routinely taken from serum creatinine (SCr) with several published formulae: Cockcroft and Gault, MDRD, CKD-EPI. Basically, all these formulae aim at predicting the endogenous creatinine production by morphological parameters (age, body weight...) However, in the elderly, muscular mass is extremely variable and sarcopenia is quite commonly encountered (frequently linked to Alzheimer disease). This is probably the main reason why the aforementioned formulae are not valid in this population: for a given renal function, a lower muscular mass induces a lower creatinine production and, henceforth, a lower SCr value, which gives an overestimation of eGFR. Muscular mass is closely linked to lean body mass (LBM), which can be properly assessed by whole-body dual X-ray absorptiometry (DXA). Alternatively, Bioelectric Impedance Spectroscopy (BIS) can also be used. Investigators postulate that it is possible to estimate GFR in the elderly from both SCr and LBM estimation from DXA. Proof of concept has already been made by others but until now, no specific formula for the elderly has been devised and properly validated. Investigators'aim is thus to propose a new formula to predict GFR from both SCr and LBM (estimated from DXA) in the elderly. This formula will be elaborated from a first series of 100 patients and validated on a second series of 100 other patients.

Interventions

measurement of lean body mass by whole-body DXA

OTHERmeasurement of morphological parameters

measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.

BIOLOGICALa blood sample

One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.

BIOLOGICALalbumin or blood in urine

dipstick analysis for albumin or blood in urine

DEVICEBioelectric Impedance Spectroscopy (BIS)

measurement of lean body mass by BIS

BIOLOGICAL51Cr-EDTA plasma clearance

measurement of 51Cr-EDTA plasma clearance to determine GFR

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

: * age of 75 years of more * origin from Western Europe or North Africa * covered by social health insurance * general health condition allowing transportation and ambulatory procedures during one day

Exclusion criteria

: * ascitis, oedema or third compartment * fast change in body weight (more than 5% in less than one week) * eGFR \< 30 mL/min/1.73 m² (using MDRD formula) * legal concerns: prisoners, guardianship, lack of health insurance, failure to consent * intake of drugs that interfere with creatinine tubular secretion * cimetidine * trimethoprim * intake of drugs that interfere with creatinine assay * calcium dobesilate * hydroxocobalamin * N-ethylglycine * phenindione * lidocaine * inability to lie during 10 minutes without moving * patients who are bedridden, hemiplegic or highly dependent on others * any health condition that, in the investigator's opinion, could rapidly (\< 1 week) vary the extracellular volume or GFR (these is voluntarily left open to the investigator because it is hardly possible to make an exhaustive list here)

Design outcomes

Primary

MeasureTime frameDescription
SCr and LBM estimated from DXAEach participant is followed for one day.The formula that will be designed (using SCr and LBM estimated from DXA) from the first 100 patient data, will match measured GFR (as given by 51Cr-EDTA clearance) with less than 10 mL/min/1.73 m² absolute error in more than 90% of the other 100 patients.

Secondary

MeasureTime frameDescription
SCr and lean body mass (by BIS)Each participant is followed for one day.A formula using SCr and measurement of lean body mass by bioelectric impedance spectrometry that will match measured GFR (as given by 51Cr-EDTA clearance) with less than 10 mL/min/1.73 m² absolute error in more than 90% of the other 100 patients.
SCr and morphological parametersEach participant is followed for one day.A formula using SCr and measurement of morphological parameters (thigh perimeter, leg perimeter, arm perimeter) that will match measured GFR (as given by 51Cr-EDTA clearance) with less than 10 mL/min/1.73 m² absolute error in more than 90% of the other 10
Accuracy of new formulaeEach participant is followed for one day.The new formulae outperform eGFR (Cockcroft and Gault, MDRD and CKD-EPI formulae) for the following criteria: better accuracy (smaller bias) according to Bland and Altman
SCr and lean body mass ( by DXA)Each participant is followed for one day.Detection of patient with impaired renal function by measuring SCr and lean body mass by DXA better than with existing formulas.
Sensitivity of new formulaeEach participant is followed for one day.The new formulae outperform eGFR (Cockcroft and Gault, MDRD and CKD-EPI formulae) for the following criteria: sensitivity to detect GFR \< 60 mL/min/1.73 m²
Specificity of new formulaeEach participant is followed for one day.The new formulae outperform eGFR (Cockcroft and Gault, MDRD and CKD-EPI formulae) for the following criteria: specificity to detect GFR \< 60 mL/min/1.73 m²
Precision of new formulaeEach participant is followed for one day.The new formulae outperform eGFR (Cockcroft and Gault, MDRD and CKD-EPI formulae) for the following criteria: better precision (smaller SD of difference) according to Bland and Altman.

Countries

France

Contacts

Primary ContactEmmanuel DURAND, Professor
durandem@club-internet.fr3 69 55 04 58

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026